VP3

Global CDC7 Kinase Inhibitors Clinical Trials & Market Insight Report 2024 Featuring Carna Biosciences, Chia Tai Tianqing Pharma, Eli Lilly, Memorial Sloan-Kettering Cancer Center, and Schrodinger - ResearchAndMarkets.com

Retrieved on: 
Thursday, January 11, 2024

The "Global CDC7 Kinase Inhibitors Clinical Trials & Market Opportunity Insight 2024" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global CDC7 Kinase Inhibitors Clinical Trials & Market Opportunity Insight 2024" report has been added to ResearchAndMarkets.com's offering.
  • The uncontrolled proliferation of cancer cells often involves dysregulation of DNA replication, and CDC7 kinase is often overexpressed in various cancer types.
  • In contrast, CDC7 kinase inhibitors focus on disrupting DNA replication process, offering a more specific and potentially less toxic approach.
  • Global CDC7 Kinase Inhibitors Clinical Trials & Market Opportunity Insight 2024 Report Highlights:
    Global CDC7 Kinase Inhibitors Clinical Pipeline By Company, Indication & Phase

Sunverge Joins RMI’s “Virtual Power Plant Partnership” with Industry Leaders

Retrieved on: 
Thursday, June 15, 2023

Sunverge, the provider of an industry-leading distributed energy resource (DER) control, orchestration and aggregation platform, today announced that it has joined RMI’s Virtual Power Plant Partnership (VP3).

Key Points: 
  • Sunverge, the provider of an industry-leading distributed energy resource (DER) control, orchestration and aggregation platform, today announced that it has joined RMI’s Virtual Power Plant Partnership (VP3).
  • Among the industry companies participating in VP3 are Google Nest, Ford, General Motors, and more.
  • “The power industry is just scratching the surface of the value that VPP’s can provide to consumers, utilities, grid, and society.
  • The company is looking forward to continuing its work on the VPP industry in tandem with industry leaders in the Virtual Power Plant Partnership.

Leap Joins Virtual Power Plant Partnership to Accelerate the Energy Transition

Retrieved on: 
Thursday, April 13, 2023

Leap , the leading platform for energy market access, today announced that it has joined the Virtual Power Plant Partnership (VP3).

Key Points: 
  • Leap , the leading platform for energy market access, today announced that it has joined the Virtual Power Plant Partnership (VP3).
  • RMI, founded as Rocky Mountain Institute, launched the VP3 initiative in January 2023 to advance virtual power plant (VPP) solutions to help decarbonize the electricity sector.
  • Through this collaboration, Leap will work closely with other leading energy technology companies, including Leap’s current technology partners Google Nest and Sunrun, to accelerate the growth of the VPP industry.
  • Wood Mackenzie recognized Leap as the leading VPP market interface by number of aggregations in its recent Virtual Power Plant market report .

AutoGrid Joins RMI's VP3 Initiative

Retrieved on: 
Thursday, March 30, 2023

REDWOOD CITY, Calif., March 30, 2023 /PRNewswire/ -- Industry-leading Virtual Power Plant (VPP) and Distributed Energy Resource Management Solution (DERMS) provider AutoGrid announced today that it has joined Rocky Mountain Institute's (RMI) Virtual Power Plant Partnership (VP3) initiative to accelerate the scaling of virtual power plants in order to enable a cleaner, more reliable, and cost-effective grid.

Key Points: 
  • With more than 7GW of flexible capacity and an annual average of 1,800 dispatch events, AutoGrid joins other industry champions including Ford, General Motors, and Google Nest to advance this critical technology in accelerating the energy transition.
  • "VP3's objectives are closely aligned with AutoGrid's mission to leverage AI and technological innovation to combat the climate crisis," said AutoGrid CEO Ruben Llanes.
  • Acquired by Schneider Electric in 2022, AutoGrid also brings Schneider's global prosumer to grid strategy to VP3.
  • "VP3 looks forward to working together with AutoGrid and other industry leaders to scale the market for VPPs."

CPower Joins Industry Leading "Virtual Power Plant Partnership" Initiative

Retrieved on: 
Tuesday, March 21, 2023

BALTIMORE, March 21, 2023 /PRNewswire/ -- CPower Energy ("CPower"), the national leader in unlocking the value of customer Distributed Energy Resources (DERs), today announced that it has joined RMI's Virtual Power Plant Partnership (VP3). The initiative aims to catalyze the industry and transform policies to support scaling virtual power plants (VPPs) in ways that help advance affordable and reliable electric sector decarbonization by overcoming barriers to VPP market growth. CPower joins industry leaders, including Ford, General Motors, and Google Nest, among others, in working toward a future where businesses, households, and communities are empowered through VPPs which can help to support cost-effective energy, emissions reductions, and a more resilient electricity grid.

Key Points: 
  • BALTIMORE, March 21, 2023 /PRNewswire/ -- CPower Energy (" CPower "), the national leader in unlocking the value of customer Distributed Energy Resources (DERs), today announced that it has joined RMI's Virtual Power Plant Partnership ( VP3 ).
  • The initiative aims to catalyze the industry and transform policies to support scaling virtual power plants (VPPs) in ways that help advance affordable and reliable electric sector decarbonization by overcoming barriers to VPP market growth.
  • "CPower was recently recognized as the North America leader for flexible capacity in Wood Mackenzie's most recent market report.
  • "VP3 is excited to partner with CPower and other industry leaders to grow the market for VPPs and ensure the energy transition doesn't miss a beat."

TSO3 Obtains New Clearance for the STERIZONE® VP4 Sterilizer

Retrieved on: 
Wednesday, May 9, 2018

The new clearance for the STERIZONE VP4 Sterilizer will allow a hospital to terminally sterilize gastrointestinal endoscopes that have dimensions within the cleared intended use.

Key Points: 
  • The new clearance for the STERIZONE VP4 Sterilizer will allow a hospital to terminally sterilize gastrointestinal endoscopes that have dimensions within the cleared intended use.
  • "In 2009, TSO3 set itself on a path to bring about lasting and meaningful change to healthcare sterilization practices.
  • This clearance allows TSO3 to partner with healthcare systems to facilitate the terminal sterilization of these devices," stated R.M.
  • More information about the STERIZONE VP4 Sterilizer is available through TSO3's website, under the Products section at http://www.tso3.com/en/products/sterizone-vp4/ .